Tudományos kitekintés – Neurológia

Management of Parkinson Disease in 2017 – Personalized Approaches for Patient-Specific Needs

Source: JAMA Parkinson disease (PD) has been described as one of the most complex syndromes encountered in clinical medicine. Long-term treatment with dopaminergic agents, the mainstay of therapy, necessitates constant recalibration and possibly additional pharmacological, behavioral, and surgical therapy. Numerous motor and nonmotor PD symptoms may complicate the diagnosis and present therapeutic challenges (Figure). Figure.(…)

Depression’s “Transcriptional Signatures” Differ in Men vs. Women

Divergent illness processes may point to sex-specific treatments   Brain gene expression associated with depression differed markedly between men and women in a study by NIMH-funded researchers.  Such divergent “transcriptional signatures” may signal divergent underlying illness processes that may require sex-specific treatments, they suggest. Experiments in chronically-stressed male and female mice that developed depression-like behaviors(…)

FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease

Approval represents the first new treatment option for chorea associated with Huntington’s disease in nearly a decade JERUSALEM–(BUSINESS WIRE)–Apr. 3, 2017– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD). Previously(…)

Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders

Source: Scrip New research offers mechanistic proof of signaling between gut and brain in Parkinson’s disease, showing that introducing an altered microbiome from PD patients into a mouse model can recreate the motor symptoms of the disease. Disruptive innovations sometimes come directly from the development of a novel enabling technology. In other cases, however, they(…)

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Source: Alzforum 09 Aug 2016 The use of biomarkers has transformed scientists’ view of Alzheimer’s disease, revealing that pathology begins to accumulate more than 20 years before clinical symptoms. This knowledge paved the way for secondary prevention trials. Now, tau PET is further changing conceptions(…)

Learn About AD Biomarker Meta-Analysis on AlzBiomarker Database

Direct Link with video to ALZFORUM In the April 8 Lancet Neurology, researchers led by Bob Olsson at the University of Gothenburg, Sweden, reported the most comprehensive meta-analysis of published Alzheimer’s disease fluid biomarker data to date. The researchers scoured literature going back 30 years for studies on 15 CSF and plasma markers of AD(…)

The genetic landscape of Alzheimer disease: clinical implications and perspectives.

Genet Med. 2015 Aug 27. doi: 10.1038/gim.2015.117. [Epub ahead of print] Van Cauwenberghe C1,2, Van Broeckhoven C1,2, Sleegers K1,2. Abstract The search for the genetic factors contributing to Alzheimer disease (AD) has evolved tremendously throughout the years. It started from the discovery of fully penetrant mutations in Amyloid precursor protein, Presenilin 1, and Presenilin 2(…)

The genetics of the epilepsies.

Curr Neurol Neurosci Rep. 2015 Jul;15(7):39. doi: 10.1007/s11910-015-0559-8. El Achkar CM1, Olson HE, Poduri A, Pearl PL. Abstract While genetic causes of epilepsy have been hypothesized from the time of Hippocrates, the advent of new genetic technologies has played a tremendous role in elucidating a growing number of specific genetic causes for the epilepsies. This(…)

Pharmacogenomic medicine in autism: challenges and opportunities

Paediatr Drugs. 2015 Apr;17(2):115-24. doi: 10.1007/s40272-014-0106-0. Bowers K1, Lin PI, Erickson C. Abstract Autism spectrum disorder (ASD) affects 1 in 68 children in the US and is distinguished by core deficits in social interactions. Developing pharmacologic treatments for ASD is complicated by clinical and genetic heterogeneity. Although pharmacological treatments have not been shown to be(…)

Biomarkers of Parkinson’s disease: present and future

Metabolism. 2015 Mar;64(3 Suppl 1):S40-6. doi: 10.1016/j.metabol.2014.10.030. Epub 2014 Oct 31. Miller DB1, O’Callaghan JP2. Abstract Sporadic or idiopathic Parkinson’s disease (PD) is an age-related neurodegenerative disorder of unknown origin that ranks only second behind Alzheimer’s disease (AD) in prevalence and its consequent social and economic burden. PD neuropathology is characterized by a selective loss(…)